HC Wainwright reaffirmed their buy rating on shares of Catalyst Pharmaceuticals, Inc. HC Wainwright now has a $6.00 target price on the biopharmaceutical company's stock.
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company.
Armenian President to Meet Putin in Moscow
Sargsyan, at the same time, briefed the attendees about the Nagorno Karabakh conflict, Armenia-Turkey relations, as well as regional issues.
Other research analysts have also recently issued research reports about the company. SunTrust Banks, Inc. reiterated a buy rating and issued a $5.00 target price on shares of Catalyst Pharmaceuticals in a report on Tuesday, September 5th. Piper Jaffray Companies set a $6.00 target price on Catalyst Pharmaceuticals and gave the stock a buy rating in a report on Monday, August 7th. BMO Capital Markets reissued a buy rating and issued a $5.00 target price on shares of Rigel Pharmaceuticals in a research note on Monday, October 2nd. Finally, BidaskClub cut Rigel Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, July 28th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Rigel Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $6.63.
Shares of Rigel Pharmaceuticals (NASDAQ:RIGL) opened at 2.50 on Wednesday. Rigel Pharmaceuticals has a 52-week low of $1.88 and a 52-week high of $4.38.
Prominent Runners: The Goldman Sachs Group, Inc. (GS), Baidu, Inc. (BIDU)
The investment management company reported $5.02 EPS for the quarter, topping analysts' consensus estimates of $4.17 by $0.85. The stock has a market cap of $90,584.94, a P/E ratio of 12.51, a price-to-earnings-growth ratio of 1.22 and a beta of 1.48.
Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its earnings results on Tuesday, November 1st. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.01. The company had revenue of $0.90 million for the quarter. Rigel Pharmaceuticals had a negative return on equity of 82.70% and a negative net margin of 255.84%. Nationwide Fund Advisors bought a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth about $111,000.
COPYRIGHT VIOLATION NOTICE: "Rigel Pharmaceuticals, Inc". If you are reading this article on another publication, it was stolen and reposted in violation of United States & worldwide copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2017/11/13/catalyst-pharmaceuticals-inc-cprx-earns-buy-rating-from-hc-wainwright.html. The shares were purchased at an average cost of $2.58 per share, with a total value of $51,600.00.
Telstra gives broadband customers unlimited data
In other words, more than half the premises in Australia can order an NBN plan from a retailer, the company said. That's why we have launched unlimited bundles for new and existing customers on our $99 and above plans.
In related news, insider Patrick J. Mcenany acquired 20,000 shares of the company's stock in a transaction dated Tuesday, September 5th. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Smith Asset Management Group LP boosted its stake in shares of Rigel Pharmaceuticals by 64.2% in the second quarter. Smith Asset Management Group LP now owns 94,380 shares of the company's stock worth $210,000 after buying an additional 36,910 shares during the last quarter. State Street Corp boosted its holdings in shares of Rigel Pharmaceuticals by 4.3% during the second quarter. ClariVest Asset Management LLC boosted its position in Rigel Pharmaceuticals by 5.5% in the second quarter. California State Teachers Retirement System boosted its position in Rigel Pharmaceuticals by 4.6% in the second quarter. JPMorgan Chase & Co. now owns 1,461,550 shares of the biotechnology company's stock worth $3,990,000 after purchasing an additional 11,836 shares during the period. Institutional investors own 40.19% of the company's stock. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases.